… cell lung cancer (NSCLC). This study aimed to compare their clinical uses and the influence
of EGFR mutation. … The usages of erlotinib and gefitinib in advanced NSCLC were analyzed. …

… and safety of erlotinib in untreated p with advanced NSCLC and mutated EGFR. Methods: …
IIIB-IV chemotherapy-naive p with confirmed NSCLC and mutated EGFR, PS 0–2, age ≥ 18 …

… erlotinib was not significantly superior to gefitinib in advanced NSCLC with EGFR exon 19 or
21 mutations … , upon treatment with erlotinib or gefitinib, patients with exon 19 mutations had …

… NSCLC p with EGFR mutations. Methods: From February 2007 to January 2011, we screened
1,227 p for EGFR mutations, and 174 patients were randomly assigned to receive erlotinib …

… Interim results from a Phase I study evaluating the safety and efficacy of nivolumab plus
erlotinib combination in an EGFR-mutant advanced NSCLC cohort, most of whom had …

… EGFR mutations were included in the trials establishing the use of PD-1 axis inhibitors in
advanced NSCLC. A … erlotinib, bevacizumab, ipilimumab, or platinum-doublet chemotherapy in …

… erlotinib (150 mg/day, n = 82) to gemcitabine (1000 mg/m 2 , D1,8, every 3 weeks) plus
carboplatin (AUC = 5, n = 72) in advanced NSCLC patients with positive EGFR mutation. Its …

… in patients with advanced NSCLC and somatic EGFR mutations initially treated with gefitinib
or erlotinib than published rates of 40% in historical series of advanced NSCLC patients. …

… Experimental Design: We assessed the T790M mutation in pretreatment diagnostic
specimens from 129 erlotinib-treated advanced NSCLC patients with EGFR mutations. The …

… The phase 1 CheckMate 012 study evaluated nivolumab plus erlotinib in patients with
EGFR-mutated advanced NSCLC. One patient was TKI-naive; 20 had received prior erlotinib. The …